Oral artesunate for HPV-related cervical precancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests an oral medication called artesunate to see if it can treat cervical precancer (CIN2/3) caused by HPV. The goal is to find a non-surgical option that may help your body clear the abnormal cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have HPV-positive cervical precancer (CIN2/3) confirmed by biopsy.
- You are generally able to care for yourself (performance status 0-2).
- Your blood counts are within acceptable ranges (checked by a doctor).
- Your kidney and liver function are adequate (checked by blood tests).
- If you could become pregnant, you will use birth control during and for 6 weeks after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether artesunate vaginal inserts can help treat high-grade abnormal cells on the cervix (CIN2/3). It’s meant for adults who have a confirmed high-grade precancer change and can use birth control during the study.
This trial tests an artesunate ointment to treat high-grade anal precancer (HSIL) in people who do not have HIV. The goal is to see if the ointment can clear the abnormal cells caused by HPV.
This trial tests an artesunate ointment for women with high-grade vulvar lesions caused by HPV. It aims to see if the ointment can help the lesions heal or disappear without needing surgery.
This trial tests a new way to prevent cervical cancer in women with both HIV and HPV. It focuses on women in India who are already on stable HIV treatment and have a normal cervical exam.
This study tests a topical gel made from curcumin (a compound in turmeric) to see if it can help clear abnormal cervical cells caused by HPV. It may be an option for women with low-grade changes or who have recently had high-grade changes treated.
This early (Phase 1) study tests a new treatment for people with long-lasting mild abnormal Pap test results (ASC-US or LSIL) who also have HPV16 found on testing. It aims to find out whether the treatment can be given safely and may affect the HPV and abnormal cell changes.
Hear when a new CIN 2/3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.